


HOME EU HCV SUMMITS MINI POLICY SUMMITS HEPATITIS C ABOUT US





HEPATITIS C

3rd EU HCV ELIMINATION POLICY SUMMIT

Wednesday 24th March 2021 14:00 to 18:30 CET

Securing Wider EU Commitment to the Elimination of HCV

☐ Online event



Securing Wider EU Commitment to the Elimination of HCV

3rd EU HCV Elimination Policy Summit Wednesday 24th March 2021 14:00 to 18:30 CET

Online event

🛂 3rd EU Policy Summit Programme (/images/summits/summit2021/20210318-3rd-EU-HCV-Policy-Summit.pdf)

(tpl://www.werhcvbrusselssummintereu/eu-

yu yu mitsi/tsvie h chev-s u m m i t-

But he main it - documents bespite the progress that has been made in recent years, HCV remains a major public health problem in Europe. In the European Region shows an estimated 15 million people have hepatitis C, which equates to 2.0% of all adults. When the elimination strategy was 2021 in May 2016, the World Health Organization (WHO) estimated that more than 7 million lives would be saved

worldwide by 2030, if targets were achieved. However, according to recent European Centre for Disease Prevention and Control (ECDC) findings, only a few European countries have met the 2020 target of the European Action Plan in diagnosing 50% of people with chronic hepatitis B or C.

In the context of strained healthcare systems and shifting priorities, largely as a result of the COVID-19 crisis, it is essential to ensure that the importance of efforts to eliminate HCV is not forgotten. If anything, the current pandemic should underline the need for widespread and effective public health responses. HCV must continue to be a priority for decision makers.

This planned four-hour virtual summit aims to bring together policy-makers, experts, members of parliament, directors of national HCV elimination plans, mayors, patient associations, clinicians and MEPs from across Europe, to raise awareness on the state of play regarding the goal of elimination of HCV by 2030 and showcase best practices as well as indicate what policy actions are needed to get more countries on track to achieve HCV elimination by 2030.

The 3rd EU HCV Policy Summit will provide an exceptional opportunity for participants to

- Review the progress made in the last five years to understand how far Europe is from achieving the goal of eliminating HCV by 2030
- · Exchange views on the role and state of diagnosis
- Evaluate the impact of the COVID-19 crisis on the viral hepatitis elimination services
- Share national-level best practice and discuss EU's position as a leader in helping deliver the elimination target

Call to Action for a Europe free of hepatitis C (24,03,2021)





Download the Call to Action

(/images/summits/summit2021/HepBCPPA_Final_Call_to_Action_24_March.pdf)

Care and Treatment of Chronic HCV

Care and treatment of chronic HCV-DEC 2020 (/images/documents/reports/Care_and_treatment_of_chronic_HCV-DEC_2020.pdf)

About us

In April 2009, a group of leading European scientists, public health experts and patient advocates created the Hepatitis B and C Summit Conferences Association as a Luxembourg-based not-for-profit Association.

The aim of the association is to urge and facilitate the formulation of public policies at national and international level for the communication, prevention and management of the spread of viral Hepatitis B and C. The Association's unique approach in furtherance of this aim is to gather together, and work in partnership with, the major stakeholders in the field of these diseases including regulators, patients, clinicians, public health and civil society communities and the private sector.

Répal brouet - us)



Welcome to the 3rd EU HCV Policy Summit site.

We are currently in the process of finalising the programme, so additional information regarding the registration, session and speakers will be uploaded in due time. In the meantime, please email afox@hepbcppa.org (mailto:afox@hepbcppa.org) if you require further information.

Official Partners





















Financial support





This event has been supported by grants from AbbVie and Gilead Sciences Europe

© Hepatitis B & C Public Policy Association 2015-2021 - Website by mijim.com (http://www.mijim.com)